Chronic Myeloid Leukemia
Last Posted: Aug 29, 2019
- Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice.
Almeida Antonio et al. Acta medica portuguesa 2019 Aug 32(7-8) 550-557
- Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
Kim Borahm et al. The Journal of molecular diagnostics : JMD 2018 Oct
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
Radich Jerald P et al. Journal of the National Comprehensive Cancer Network : JNCCN 2018 Sep 16(9) 1108-1135
- Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration
SM Boca et al, JCO Precision Oncology, September 2018
- Molecular biology as a tool for the treatment of cancer.
de Castro Sant' Anna Carla et al. Clinical and experimental medicine 2018 Jul
- Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.
Shokeen Yogender et al. Ethiopian journal of health sciences 2018 Mar 28(2) 135-146
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease.
Branford Susan et al. Blood 2018 Jul
- Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.
Ankathil Ravindran et al. Pharmacogenomics 2018 Mar
- Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis.
Cargnin Sarah et al. Pharmacological research 2018 Feb
- TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.
Weich Natalia et al. Blood cells, molecules & diseases 2016 Jul 59129-33
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
- NIH Information (2)
- COVID-19 (1)
- Human Genome Epidemiologic Studies (236)
- GWAS Studies (2)
- Human Genomics Translation/Implementation Studies (8)
- Genomic Tests Evidence Synthesis (1)
- Genomic Tests Guidelines (3)
- Tier-Classified Guidelines (1)
- Non-Genomics Precision Health (2)
- Reviews/Commentaries (7)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.